Biocryst Pharmaceuticals (BCRX) Shares Outstanding (Diluted Average) (2013 - 2026)

Biocryst Pharmaceuticals has reported Shares Outstanding (Diluted Average) for 14 years, with the latest figure at $242.3 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) rose 12.54% year-over-year to $242.3 million; the trailing twelve-month figure through Mar 2026 stood at $242.3 million (up 12.54% YoY), and the FY2025 full-year result was $218.6 million, up 5.75% from the prior year.
• Shares Outstanding (Diluted Average) for Q1 2026 stood at $242.3 million, up from $218.6 million in the prior quarter.
• The five-year high for Shares Outstanding (Diluted Average) was $242.3 million in Q1 2026, with the low at $184.9 million in Q1 2022.
• Historically, Shares Outstanding (Diluted Average) has averaged $202.4 million across 5 years, with a median of $206.1 million in 2024.
• Annual changes were most pronounced in 2023 — Shares Outstanding (Diluted Average) advanced 1.95% — and 2026, when it rose 12.54%.
• Biocryst Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $185.9 million in 2022, then advanced by 3.38% to $192.2 million in 2023, then gained by 7.54% to $206.7 million in 2024, then advanced by 5.75% to $218.6 million in 2025, then rose by 10.83% to $242.3 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $242.3 million (Q1 2026), $218.6 million (Q4 2025), and $219.9 million (Q3 2025), per Business Quant data.